Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.080
-0.110 (-2.63%)
Feb 21, 2025, 4:00 PM EST - Market closed
Alterity Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Alterity Therapeutics stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 96.08% from the current stock price of 4.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alterity Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +194.12% | Jan 30, 2025 |
Maxim Group | Maxim Group | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +96.08% | Dec 12, 2024 |
Benchmark | Benchmark | Buy Reiterates $4 | Buy | Reiterates | $4 | -1.96% | Mar 7, 2024 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $20 → $10 | Strong Buy | Maintains | $20 → $10 | +145.10% | Jun 5, 2023 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +390.20% | Aug 3, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.